and TSH transcription. Individuals with mutations in POU1F1 present with combined deficiency of 28 GH, PRL, and TSH. Here we identified a heterozygous missense mutation with evidence of 29 pathogenicity, at the POU1F1 locus, in a large family in which isolated growth hormone deficiency 30 segregates as an autosomal dominant trait. The corresponding p.Pro76Leu mutation maps to a 31 conserved site within the POU1F1 transactivation domain. Bandshift assays revealed that the mutation 32 alters wild-type POU1F1 binding to cognate sites within the hGH-LCR and hGH1 promoter, but not to 33 sites within the PRL promoter, and it selectively increases binding affinity to sites within the hGH-34
Introduction 45
Pituitary development is temporally and spatially regulated by numerous signaling molecules 46 and transcription factors (1) . The Pou-homeodomain protein, Pou1f1, initially named Pit1, plays a key 47 7 top). The reporter plasmid was co-transfected into HEK293T cells along with a plasmid expressing the 153 WT or the P76L POU1F1 protein. Western analysis of three independent studies revealed that the 154 mutant protein was expressed at levels equal to or greater than the WT POU1F1 (Fig 2B and data not  155 shown). The co-transfection with the WT POU1F1 protein increased luciferase reporter activity by 5-156 fold over that of an empty vector. The transcriptional enhancement of the luciferase reporter by the 157 P76L POU1F1 was 50% relative to the WT (Fig 2B) . It was additionally noted that co-transfection of 158 equal amounts of the plasmid encoding the POU1F1 proteins did not inhibit the transcriptional activity 159 associated with the wild-type POU1F1 protein (Fig 2C) . These data lead us to conclude that the P76L 160 POU1F1 mutation results in a decrease in transcriptional activity of the GH gene, but argue against a 161 dominant effect of the mutant protein, at least in the context of defined reporter assay. 162
POU1F1_P76L has a differential impact on POU1F1 binding to cognate sites at HSI of the hGH 163

LCR and at the GH1 promoter 164
The decreased transcriptional capability of POU1F1_P76L prompted us to compare the 165 binding affinity of the WT and mutant POU1F1 protein towards a subset of cognate binding targets. This was done by subjecting bacterially generated WT and P76L POU1F1 proteins to surface plasmon 167 resonance (SPR) analysis. For purposes of the analysis, the WT and mutant proteins were generated in 168 parallel with all culture and purification steps held constant. Of note, we observed a 40-fold higher 169 recombinant protein yield from the bacterial cultures expressing the WT vs the mutant protein. This 170 difference appeared to reflect the formation of inclusion bodies in cultures of the mutant protein 171 because the yield of the mutant protein was increased by culturing at lower temperature. This 172 difference in solubility is consistent with an altered conformation of the POU1F1_P76L protein.
173
Biotinylated DNA targets representing the defined POUF1 binding sites of the hGH1 promoter and of 174 HSI were immobilized on a streptavidin (SA) sensor chip and used for the analysis. 175
For a first qualitative test, equal amounts of the purified recombinant POU1F1_WT and 176 POU1F1_P76L proteins (quantified by Experion; see Methods) were then loaded as analytes. The 177 recorded resonance units (RU) showed that the WT and P76L POU1F1 proteins bind the promoter and 178 the HSI DNA targets; the difference of 11RU on HSI target is significant. This result allows us to8 conclude that POU1F1_P76L binds better than POU1F1_WT at the same concentration under our 180 assay conditions (Fig. 3A) . As a control, we performed similar experiments with a recombinant form 181 of POU1F1 carrying a previously identified CPHD missense mutation (24). This mutation in a 182 conserved residue of the homeodomain abolishes the binding of POU1F1 to its DNA targets 183 demonstrated by a dramatic loss of binding in our SPR analysis (Fig 3A) . 184
We next evaluated the affinity of the WT and the P76L proteins for their DNA targets in a set 185 of kinetic binding studies (see Methods). The dissociation constants obtained on the GH1 promoter 186 measured using various concentrations of those proteins were similar for the POU1F1_WT and the 187 
PRL promoter 198
We next compared by EMSA the binding of the WT alone, the POU1F1_P76L alone, and a 199 mix of the two proteins, as would occur in individuals heterozygous for the P76L mutation. Binding 200 was assessed for DNA fragments containing the full set of POU1F1 binding sites (HSI and GH1 201 promoter) or each of the corresponding individual POU1F1 binding sites (HSI-A,B,C and prox-GH1, 202 prox-GH2). Remarkably, the migration patterns were different for the DNA incubated with 203 POU1F1_WT (lane 2), POU1F1_P76L (lane 3) and the mix of these two proteins (lane 4) for the HSI 204 (Fig. 4A-D) and for the hGH1 promoter sites (Fig. 4E-G) . These data suggest a modified binding 205 conformation of the WT/mutant dimer (POU1F1_WT/POU1F1_P76L) complex on all POU1F1 206 binding sites of the GH1 promoter and HSI. Of note, the POUF1_WT/POU1F1_P76L mix showed the 207 same migration pattern as POU1F1_WT when assayed for binding to the prolactin promoter (i.e. PRL-208 1 and PRL-2) (Fig. 4H, I ). These data are consistent with the disease phenotype characterized by a 209 deficit in GH with no PRL deficiency. 210
The P76L mutation increases the interaction of POU1F1 with three different POU1F1 211
transcriptional cofactors 212
The impact of the POU1F1 mutation on complex formation with two pituitary-specific (PITX1 213 and LHX3a) transcriptional cofactors and one ubiquitous transcription factor (ELK1) was assessed by 214 co-immunoprecipitations after cotransfection in HEK293T cells of an expression plasmid encoding the 215 HA-tagged POU1F1_WT or POU1F1_P76L with a plasmid encoding PITX1, LHX3a or ELK1. 216
Nuclear proteins were immunoprecipitated with an anti-HA antibody and the pellets were 217 subsequently assayed for each cofactor by western blot (Fig. 5, left panel) . In parallel the nuclear 218 proteins were also immunoprecipitated with antibodies directed against each cofactor and the western 219 blots were revealed with an anti-HA-antibody (Fig. 5, right panel) . The data revealed that the P76L 220 mutation enhances complex formation with each partner by 5 -10 folds when compared to the WT 221 POU1F1 protein (Fig. 5A , 5B, 5C). A formal possibility is that the difference in amount of complex 222 observed is due to the POU1F1_P76L conformational difference which would make the protein 223 complex more accessible the HA-tag to antibody. Co-immunoprecipitations performed with antibodies 224 directed against each of the interacting proteins allowed us to rule out this possibility. 225
To further evaluate the importance of the peptide surrounding Pro76 in these interactions, we 226 performed similar co-immunoprecipitation experiments with different POU1F1 mutants in which 227
Pro76 and the neighboring (Leu74, Thr75, Cys77 and Leu78) were each individually replaced by 228 alanine residues. The amount of complex formed with PITX1 and LHX3a ( Fig. 6A and 6B , 229 respectively) was increased most prominently by the P76A and P76L substitutions. Moreover, with 230 ELK1 cofactor (Fig. 6C) , the leucine substitution seemed to have a critical impact since an alanine did 231 not modify the amount of complex formed. These data demonstrate a major role of the Pro76 residue 232 in the interaction of the POU1F1 trans-activating domain with at least three partners. 233 A mouse model of the P76L mutation confirms the adverse impact on gene expression but fails 234 to recapitulate the dominant inheritance pattern 235
To study the functional consequences of the P76L mutation in an in vivo context, we 236 introduced the P76L mutation into the mouse Pou1f1 locus (see Methods and Fig. 7A ). The expression 237 of P76L encoding Pou1f1 mRNA was confirmed in the pituitaries of P76L/wt mice and the mRNA 238 from the mutant allele was shown to be expressed at equivalent levels to the WT allele by a 239 comparative RT/PCR (Fig. 7B) . Remarkably, however, the expression of the mutant Pou1f1_P76L 240 protein was markedly suppressed, with steady state levels in the mouse pituitary less than 10% of 241 output from the endogenous WT locus (Fig. 7C, asterix) . The expression of mRNA from each of three 242 endogenous Pou1f1-dependent genes (mGh, mPrl, mTsh) were assessed and found to be unaltered in 243 mice heterozygous for the P76L mutation (data not shown). Similarly, the expression of the hGH1 244 gene from the hGH/BAC transgene in the P76L heterozygous mouse was expressed at normal levels 245 (data not shown). Consistent with the low level expression of Pou1f1 from the mutant locus, mice 246 homozygous for the P76L mutation displayed a dwarf phenotype (Fig. 7D) . Overall, these data point 247 POU1F1 is essential for the formation of the somatotrope, lactotrope, and a subset of the 252 thyrotrope lineages. As such, all POU1F1 mutations thus far reported are linked to combined pituitary 253 hormone deficiency (CPHD) comprising decreases in expression of GH, PRL and TSH (25). In the 254 current study, we report the first example of a POU1F1 mutation that is linked to an isolated GH 255 deficiency. Functional data reveal that the P76L mutation, located in a highly conserved segment of 256 the transcriptional activation domain (TAD), impacts on the binding patterns of POU1F1 and on the 257 interaction of POU1F1 with protein partners. The predicted conformational change induced by the 258 non-conservative substitution of a proline for a leucine is consistent with the low steady state levels of 259 the mutant protein in the mouse despite normal levels of mRNA synthesis. Thus the P76L missense 260 mutation results in an unusual situation: a specific disruption of the human GH1 gene expression. 261
Several lines of evidence demonstrate that the P76L variation identified in POU1F1 is a 262 disease-causing mutation. First, the strict co-segregation of the phenotype with this mutation in 9 263 individuals over 3 generations. Second, the transcriptional activity of the POU1F1_P76L on the 264 chimeric LCR-hGH1 promoter is significantly lower than that of POU1F1_WT. Third, using SPR 265 assays, we show that the P76L mutation leads to an increased affinity of POU1F1 for the LCR sites. 266
Fourth, bandshift assays reveal that the DNA binding pattern of a mix of POU1F1_WT and 267 POU1F1_P76L is different from that of POU1F1_WT alone on all five cognate binding sites in the 268 hGH LCR and GH1 promoter but not on the two cognate sites in the PRL binding sites. Fifth, as 269
shown by co-immunoprecipitation studies, the P76L mutation increases the interaction of POU1F1 270 with three of its known cofactors: PITX1, LHX3a and ELK1. 271
A predicted impact of the POU1F1_P76L mutation on conformation is consistent with the 272 noted low yield of the mutant protein compared to the WT protein in two distinct settings; in E. Coli 273 and in mice carrying the heterozygous Pou1f1 mutation. It should be noted, however, as a formal 274 possibility that the low protein expression in the mouse model may be contributed to by the presence 275 of the myc epitope tag which was present at the mutant locus but not at the wt Pou1f1 locus. 276 Noteworthy, two additional missense mutations have been identified in the human POU1F1 277 TAD, P14L (26) and P24L (27). Both of these mutations result in a dominantly inherited form of 278 pituitary deficit. However, in both cases, the patients displayed a classical CPHD phenotype rather 279 than the isolated GH loss currently being reported. The mutation site within the TAD, therefore 280 appears critical in terms of phenotypic consequences. The 3D-structure of the POU1F1 TAD remains 281 undefined and in silico modeling could not be performed to test the relative impacts of the P76L, P14L 282 and P24L mutations on the three dimensional structure. Of note, however, all three of these constitute 283 a non-conservative substitution of proline for leucine that is predicted to have a major impact on 284 protein secondary structure and tertiary folding. 285 Our attempt to model the P76L mutation in the mouse was informative in a number of 286 respects. This mutation once introduced into the mouse Pou1f1 locus had no adverse effect on the12 level of mRNA generated from the locus. Notably however, the steady level of mutant protein 288 expressed from the P76L locus was markedly suppressed. Mice heterozygous for the mutation had no 289 appreciable decrease in size while mice homozygous were markedly dwarfed. Thus this mutation 290 results in a recessive dwarf phenotype in the mouse rather than the dominantly inherited phenotype in 291 the human kindred, for which, haploinsufficiency cannot be the mechanism underlying the dominant 292 expression of the disease phenotype since the heterozygous parents of patients with homozygous 293 POU1F1 null mutation have a normal phenotype. Our in vitro data on the coexpression of the mutant 294 and wild-type POU1F1 proteins argue against a dominant negative effect of the mutant protein over 295 the wild-type. 296
The data favors a hypothesis of a toxic gain of function associated with the P76L mutation in 297 humans for two reasons. First, the POU1F1_P76L protein binds the LCR sites with an increased 298 affinity, as compared to POU1F1_WT; this affinity difference might disrupt POU1F1_WT DNA 299 binding at the LCR target sites in heterozygous patients. It is therefore tempting to speculate that the 300 mutation could result in a higher occupancy at hGH LCR target sites precluding the binding of 301 POU1F1_WT. Second, we observed that the P76L mutation increases the interactions with three 302 different cofactors. The mutant protein might therefore titrate POU1F1-interacting proteins leading to 303 a competition with the wild-type POU1F1 protein. Moreover, co-immunoprecipitation-alanine-304 scanning experiments revealed that the amino acid 76 precisely is critical for these interactions; the 305 weak equilibrium of the hGH1 transcriptional complex should be modified through the ability to 306 recruit somatotrope specific cofactors necessary for high GH1 transcriptional level. Our data in 307 bandshift assays on the PRL promoter target sites are fully in accordance with the phenotype of the 308 patients with the P76L mutation who had no prolactin deficiency. 309
Of particular interest is the finding that the POU1F1_WT binds more tightly to promoter sites 310 than those within the LCR. Previous studies have demonstrated that POU1F1 occupies its cognate sites 311 in the hGH1 promoter and at HSI of the hGH LCR with distinct conformations reflecting a single base 312 pair difference (23). Thus the missense mutation at position 76 could differentially impact on POU1F1 313 actions at the hGH promoter via alterations of HSI function. Such alterations could explain the specific 314 impact of the mutation on the human hGH gene as the mGh gene is lacking the HSI enhancer and the 315 determinants. 317
In conclusion, the P76L mutation, which segregates perfectly with the severe growth 318 retardation, involves a conformation modification of the POU1F1 protein that affects cofactors and 319 DNA interactions that impact specifically the hGH1 transcriptional level of expression. This 320 constitutes a novel mechanism underlying a dominant form of IGHD in humans, also suggesting that 321 POU1F1 gene should be screened for this phenotype. 322 323
Materials and methods 324
Patients 325
All individuals studied in the reported kindred provided their written informed consent to perform 326 genetic studies. All were referred to the pediatric endocrinology outpatient clinic of the Nancy 327
Medical School hospital (CHU of Nancy). Clinical details were assessed using an information sheet 328 established by our laboratory. 329
Hormonal investigations and magnetic resonance imaging (MRI) 330
GH plasma values were evaluated after pharmalogical stimulations by arginine and ornithine, prolactin 331 level before and after TRH stimulation, total and free T4 levels, all were measured according to 332 methods at the time of diagnosis. Pituitary MRI was performed on a 0.5T General Electrics MR max 333
instrument. 334
Mutation search 335
Genomic DNA was isolated from blood samples obtained from each individual using standard 336 technique. All coding exons and intron-exon boundaries of the GH1, LCR-GH1 (AF_010280), 337 GHRHR, GHRH, GHSR, GHRL, HESX1, PROP1 and POU1F1 (NM_000306) genes were amplified 338 using sets of primers available on request. Sequences were performed according to the thermal cycle 339 sequencing Big dye terminator protocol (ABI Prism 310 Genetic Analyser, PerkinElmer Applied 340 Biosystems). 341
Plasmid constructs 342
The full-length POU1F1, and LHX3a cDNAs (9) were subcloned into the pcDNA4 or pcDNA3 343 expression vectors in which HA or Flag tags were inserted in C-terminal, respectively. The PITX1 344 cDNA, amplified from pituitary cDNA (Clonetech), was cloned into pcDNA3. The ELK1 cDNA was 345 subcloned from pCGN-ELK1 (Addgene, 27156) into pcDNA3 containing a tag Flag in C-terminal. 346
The QuikChange Site-Directed Mutagenesis Kit (Stratagene) was used to generate plasmids encoding 347 different POU1F1 mutants, pcDNA4-POU1F1-HA-(P76L, L74A, T75A, P76A, C77A, L78A). 348
The luciferase reporter plasmid was constructed as follows: 406bp of the LCR (HSI, including the 349 three POU1F1 target sites, AF_010280) and 494bp of the promoter (including the two POU1F1 350 binding sites) were linked after amplification using compatible restriction enzyme sites and subcloned 351 into the pGL3-basic-Luciferase plasmid (Promega) to obtain pGL3-chimer[LCR-promGH] plasmid 352 (Fig. 2B) . 
Luciferase activity assays and western blot 358
HEK293T cell extracts were prepared and assayed for luciferase activity, using the Promega assay 359 system, 48h after co-transfection of the pGL3-chimer[LCR-promGH] reporter gene (100ng) together 360 with either the empty pcDNA3 expression vector and/or the POU1F1-cDNA WT and/or mutant 361 pcDNA4 constructs at different amounts. Each transfection experiment was carried out in triplicate 362 and was independently replicated at least three times. Cell extracts were separated on a 10% 363 polyacrylamide gel, then transferred to a nitrocellulose membrane and probed with an anti-POU1F1 364 polyclonal antibody (sc-16288, Santa Cruz Biotechnology) and an anti-tubulin polyclonal antibody 365 (2148, Cell Signaling). 366
Protein purification 367
The full-length POU1F1 cDNA was cloned at the BamHI NotI sites into the pGEX-6P-1 vector (GE 368 Healthcare) including a PreScission protease site to remove the GST tag. GST-tagged fusion proteins 369 were produced in the BL21 DE3 star strain of Escherichia coli (Invitrogen). After induction for 3 h 370 with 0.5 mM isopropyl-β-d-thiogalactopyranoside at 37°C for the GST-POU1F1_WT, at 25°C during 371 4h for the GST-POU1F1_P76L, at 15°C for 4h for the GST-POU1F1_R265W, the bacterial pellet was 372 freezed/thawed 3 times followed by sonication in PBS1X (200 ml/L of culture), 1% Triton X-100, 373 10% glycerol and 1mg/ml lysozyme and finally clarified by centrifugation at 22.000×g for 20 min. 374
Supernatants were incubated 30mn at room temperature with glutathione-Sepharose beads (GE 375 Healthcare), then washed 4 folds in PBS1X. The last wash was performed in cleavage buffer (50mM 376
Tris-HCl pH7.0, 150mM NaCl, 1mM EDTA, 1mM PMSF), then beads were incubated 4h at 4°C with 377 600µl of PreScission protease (1U/µl, GE Healthcare) in 40ml of a cleavage buffer. Centrifugation of 378 beads at 500g 15mn at 4°C allowed to collect soluble purified protein which is concentrated on 379
Corning Spin-X UF 20ml, 10000 MWCO. Two to 5ml of protein were dialyzed in HBS buffer (10mM 380 HEPES pH7.4, 150mM NaCl, 3 mM EDTA) overnight. All preparations of proteins were checked on 381 Experion (BioRad) instrument for their quality and quantification. 382
Surface Plasmon Resonance analysis 383
Real-time DNA-protein interaction assays were performed using a Biacore 3000 instrument controlled 384 by Biacore 3000 Control Software v4.1 (GE Healthcare). All experiments were done at 25°C. After 385 preincubation in 1M NaCl, 50mM NaOH for 1min (3 times), 75µl of 500nM biotinylated DNA was 386 covalently coupled to a streptavidine (SA) sensor chip (GE Healthcare) (5µL/min) in HBS-EP running 387 buffer [10 mM Hepes (pH7.4), 150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20]. The chip was 388 then washed 1min (5µL/min) with 1M NaCl, 50mM NaOH. Real-time monitoring was displayed in a 389 sensorgram as the resonance unit (RU) versus time (s). The 70-bp fragment of the GH1 promoter (two 390 POU1F1 binding sites) was generated by annealing a sense (5' biotinylated) and antisense 391 oligonucleotide and 900RU were obtained. A 212-bp PCR product corresponding to the HSI (three 392 POU1F1 binding sites) was amplified from genomic DNA using a biotinylated primer and 1900RU 393 were anchored. Binding studies were performed during 5min with 25µl of 50nM purified protein in 394 HBS-EP, 1mM MgCl2. The chip surface was regenerated using 0.1%SDS (flow rate: 30μl/min; 395 contact time: 30s). Kinetic studies were performed at least in triplicate. Defined concentrations (from 0 396 to 50nM) of POU1F1 proteins were injected with a 5min association phase and 8min dissociation 397 phase and their dose dependency response was measured. Data were analysed with BIAevaluation 398 software 4.1 and the Kd dissociation constant was determined using the Fit kinetic simultaneous 399 were subjected to a 5% or 6% native polyacrylamide gel electrophoresis and transferred using the 428 PierceG2 Fast-blotter system (Thermo-Scientific) to a nylon membrane (Biodyne B, Pierce). After 429 transfer, the membrane was immediately cross-linked (UV Stratalinker 2400, Stratagene) using 430 autocrosslink program. A chemiluminescent method utilizing a luminol/enhancer solution and a stable 431 peroxide solution (Pierce) was used as described by the manufacturer. 432
Mouse model 433
The P76L mutation was introduced into the mouse genome via standard homologous recombination in We thank all patients and family members for their cooperation. antibodies for LHX3a (B) and ELK1 (C) on nuclear extracts samples. Western blots were generated 599 using an anti-HA antibody. Quantification of the complex formed, represented by histograms (right 600 side), was evaluated as the ratio of protein immunoprecipitated to protein expressed (input). 601 Empty 600 300 300 -400 400 -500 500 -WT -300 -300 400 -400 500 -500 P76L --300 300 -400 400 -500 500
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